Clinical Study
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
| Event | All | Grades number of patients (% of category) | Number of patients (% of total ()) | 1 | 2 | 3 | 4 |
| Mucositis | 3 (43) | 2 (67) | 1 (33) | | | Fatigue | 3 (43) | 1 (33) | | 2 (67) | | Hypertriglyceridemia | 3 (43) | 1 (33) | 2 (67) | | | Peripheral edema | 2 (29) | | 1 (50) | 1 (50) | | Anorexia | 2 (29) | 2 (100) | | | | Diarrhea | 2 (29) | 1 (50) | 1 (50) | | | Rash | 2 (29) | 1 (50) | 1 (50) | | | Pneumonia | 2 (29) | 1 (50) | | 1 (50) | | Liver function disorders | 2 (29) | 1 (50) | 1 (50) | | | Hypercholesterolemia | 2 (29) | 1 (50) | | 1 (50) | | Hypophosphatemia | 2 (29) | 2 (100) | | | | Hypoparathyroidism | 2 (29) | 2 (100) | | | | Weight loss | 1 (14) | 1 (100) | | | | Nausea | 1 (14) | 1 (100) | | | | Vomiting | 1 (14) | 1 (100) | | | | Constipation | 1 (14) | 1 (100) | | | | Allergic reaction | 1 (14) | | 1 (100) | | | Dry skin | 1 (14) | 1 (100) | | | | Itch | 1 (14) | | 1 (100) | | | Asthenia | 1 (14) | 1 (100) | | | | Anemia | 1 (14) | | 1 (100) | | | Hyperglycemia | 1 (14) | | | 1 (100) | | Cough | 1 (14) | | 1 (100) | | | Dyspnea | 1 (14) | 1 (100) | | | | Pneumonitis | 1 (14) | | | 1 (100) | |
|
|
All AEs graded according to Common Terminology Criteria for Adverse Events version 4.0.
|